Abstract
Definitive chemoradiation (CRT) followed by durvalumab is the standard of care in stage III NSCLC. Osimertinib showed high efficacy in metastatic and resectable settings and is currently assessed in unresectable IIIA/B. This study aimed at testing the efficacy of osimertinib as induction therapy before definitive radiotherapy (RT) in EGFRm stage III patients to induce tumor shrinkage and reduction of the radiation field.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call